NCI-H2444 Cells

NCI-H2444 is a human non-small cell lung cancer (NSCLC) cell line classified within the lung adenocarcinoma spectrum. It was established from a lung tumor specimen obtained from an adult patient and represents an epithelial malignancy of pulmonary origin. As part of large-scale pharmacogenomic and multi-omics characterization efforts, NCI-H2444 has been molecularly profiled alongside extensive panels of human cancer cell lines, enabling integration of genomic, transcriptomic, and pharmacological response data.

In comprehensive drug sensitivity studies of over 1,000 cancer cell lines screened against hundreds of anti-cancer compounds, lung cancer models such as NCI-H2444 have been used to correlate oncogenic alterations with therapeutic vulnerabilities :contentReference[oaicite:0]{index=0}. These analyses incorporate somatic mutation profiles, copy number alterations, DNA methylation patterns, and gene expression data to define clinically relevant cancer functional events and associate them with differential drug response. Such datasets allow NCI-H2444 to be positioned within lineage-specific and mutation-driven sensitivity clusters, supporting its application in biomarker discovery and targeted therapy evaluation.

Proteomic profiling efforts across hundreds of human cancer cell lines have further expanded the molecular annotation framework applicable to models such as NCI-H2444 :contentReference[oaicite:1]{index=1}. High-resolution mass spectrometry-based quantification of thousands of proteins enables integration of proteome-level measurements with transcriptomic and pharmacological datasets. This systems-level characterization facilitates the identification of protein biomarkers predictive of drug response and supports mechanistic studies of pathway activation, post-transcriptional regulation, and therapeutic resistance in lung adenocarcinoma models.